1Wunderlich H,Hindermann W,Huller M,et al.The correlation of p53 protein overexpression and p53 antibodies in serum of patients with transitional cell carcinoma of the urinary bladder[J].Urol Int,2000,64:13-7.
2Andrew M,Davidoff J,Dirk Igjehart,et al.Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers[J].Medical sciences,1992,89:3439-3442.
3Kuhn HM.Kromminga A,Flammann HT,et al.p53 autoantibodies in patients with autoimmune diseases: a quantitative approach[J].Autoimmunity,1999,31:229-35.
4Von Brevern MC,Hollstein MC,Cawley HM,et al.Circulating anti-p53 antibodyies in esoplageal cancer patients are found predominantly individuals with p53 core domain mutations in their tumors[J].Cancer Res,1996,56:4917-21.
5Rosenfeld MR,Malats N,Schramm L.et al.Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer[J].J Natl Cancer Inst,1997,89:381-5.
6Shiota G,Ishida M,Noguchi N,et al.Circulating p53 antibody in patients with colorectal cancer:relation to clinicopathologic features and survival.Dig Dis Sci[J],2000,45:122-8.
7Raedle J,Oremek G,Truschnowitsch M,et al.Clinical evaluation of autoantibodies to p53 protein in patients with chronic liver disease and hepatocellular carcinoma[J].Eur J Cancer,1998,34:1198-203.
8Shimada H,Takeda A,Arima M,et al.Serum p53 antibody is a useful tumor marker insuperficial esophageal squamous cell carcinoma[J].Cancer,2000,89:1677-83.
9Regele S,Kohlberger P,Vogl FD,Serum p53 autoantibodiesin patients with minimal lesions of ductal carcinoma in situ of the breast[J].Br J Cancer,1999,81:702-4.
10Brool R,Duchrow M,Oevermann E,et al.p53 autoantibodies in sera of patients with a colorectal cancer and their association to p53 protein concentration and p53 immunohistochemistry in tumor tissue[J].Int J Colorectal Dis,2001,16:22-27.
